Sebana Medical

Company Overview

Snapshot

Founded in January 2012, Sebana Medical operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of its proprietary SEBA platform. A key milestone for the company was securing patents for its technology, as reported in January 2014.

Business overview

Sebana Medical specializes in the development, manufacturing, and commercialization of products utilizing its proprietary SEBA platform, which incorporates advanced Biologic Matrix Slow-Release Technology. This technology is designed to revolutionize the delivery of therapeutic solutions, particularly for autologous fat grafts, by preventing fat reabsorption in soft tissue augmentation. The company aims to prove the efficacy and commercialize SEBA for dermal filling with autologous fat, serving the Health Tech & Life Sciences sector, with applications extending to dermatology, skin care, and tissue regeneration.

Company Intelligence Q&A

What is Sebana Medical's core technology?

Sebana Medical's core technology is its proprietary SEBA platform, which utilizes advanced Biologic Matrix Slow-Release Technology to prevent autologous fat reabsorption in soft tissue augmentation and other cosmetic indications.

When was Sebana Medical founded?

Sebana Medical was founded in January 2012.

What is the primary focus of Sebana Medical's product development?

Sebana Medical is focused on developing and commercializing its SEBA platform for treating fat grafts for dermal filling, aiming to prevent fat resorption and ensure long-lasting effects of autologous fat grafts.

What is the current stage of Sebana Medical's product development?

Sebana Medical's product is currently in the R&D stage, with preclinical studies demonstrating the safety and efficacy of SEBA, paving the way for future clinical trials.

What markets does Sebana Medical target?

Sebana Medical targets geomarkets including Spain and Germany, focusing on the Health Tech & Life Sciences sector.